The IND clearance and $95.1M capital raise remove near-term financing risk and fund the DUET Phase 1b/2a study through initial data expected in H2 2027. The large warrant overhang (9.1M shares) at $11.54 strike may cap upside near that level. Watch for first patient dosing in Q4 2026 and initial data readout in H2 2027 as key catalysts.
Price Chart
Executive Summary
Surrozen closed the second and final tranche of its March 2025 private placement, raising ~$95.1M in gross proceeds following FDA clearance of the IND for SZN-8141. The company now has ~17.8M shares outstanding, plus 3.8M pre-funded warrants and 9.1M common stock warrants, with expected cash runway into 2029 to fund the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143.
Key Financial Metrics
Key Facts
- Second closing of March 2025 private placement raised ~$95.1M in gross proceeds
- FDA cleared IND for SZN-8141 on October 2, 2026, triggering the second closing milestone
- Issued 5,741,605 shares of common stock, pre-funded warrants for 2,456,500 shares, and Series E warrants for 4,099,052 shares
- Purchase price per share and pre-funded warrant was $11.60 and $11.5999, respectively
- Series E warrants have an exercise price of $11.54 per share, exercisable immediately, expiring in 5 years
- Post-closing: ~17.8M shares outstanding, 3.8M shares issuable upon exercise of pre-funded warrants, 9.1M shares issuable upon exercise of outstanding common stock warrants
- Expected cash runway into 2029, funding DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143
- Registration statement for resale of shares to be filed within 30 days
Financial Impact
~$95.1M gross proceeds from second tranche closing, extending cash runway into 2029
Risk Factors
- Substantial dilution: post-closing fully diluted share count exceeds 30M shares, up from ~10.9M at Q1 2026
- Warrant overhang of 9.1M shares at $11.54 may pressure stock price near that level
- Clinical-stage biotech with no approved products; SZN-8141 and SZN-8143 are in early-stage development
- Registration statement for resale shares could create near-term selling pressure
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-426828 |
| Document: srzn-ex99_1.htm | 0001193125-26-426828 |
| Document: 0001193125-26-426828-index-headers.html | 0001193125-26-426828 |
| Document: 0001193125-26-426828-index.html | 0001193125-26-426828 |
| Document: 0001193125-26-426828.txt | 0001193125-26-426828 |
| 8-K Data (Synthetic) | 0001193125-26-426828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $25.48 | awaiting T+5 | — | $27.28 (+7.06%) |
Oct 20, 2026 6d ago | 8-K | $25.32 | awaiting T+5 | — | $27.28 (+7.74%) |
Oct 20, 2026 6d ago | Press Release | $25.32 | awaiting T+5 | — | $27.28 (+7.74%) |
Oct 7, 2026 19d ago | SC 13G/A | $27.97 $25.07 | ▼ −10.37% | ▼ −10.09% | $27.28 (−2.47%) |
Oct 2, 2026 24d ago | 8-K | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Oct 2, 2026 24d ago | Press Release | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Oct 1, 2026 25d ago | SC 13G | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Aug 7, 2026 11w ago | 25-NSE | $25.09 $23.78 | ▼ −5.22% | ▼ −5.17% | $27.28 (+8.73%) |
May 4, 2026 25w ago | Insider Cluster | $32.07 $29.28 | ▼ −8.70% | ▼ −11.64% | $27.28 (−14.94%) |
Mar 23, 2026 31w ago | S-3 | $25.00 $29.13 | ▼ −16.52% | ▼ −16.94% | $27.28 (−9.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers